The Neotorch randomized phase III clinical trial was designed to evaluate whether the addition of perioperative toripalimab [programmed cell death 1 (PD-1) inhibitor] to platinum-based chemotherapy ...

The best multimodal approach for resectable locally advanced esophageal adenocarcinoma is unclear. An important question is whether perioperative chemotherapy is preferable to preoperative ...

(San Diego, Calif--September 8, 2024, 10:05 a.m. PCT) – New data from landmark analysis presented today report a decreased risk of disease recurrence or death in patients with resectable NSCLC who ...

New data from landmark analysis presented today reports a decreased risk of disease recurrence or death in patients with resectable NSCLC who received adjuvant nivolumab following neoadjuvant ...

Please provide your email address to receive an email when new articles are posted on . Addition of perioperative durvalumab to standard chemotherapy improved outcomes for locally advanced gastric ...

At a median follow-up of 67 months in the phase III trial, there were no significant differences between groups in terms of overall survival (OS) or progression-free survival (PFS), reported Trevor ...

Preoperative CRT and chemotherapy significantly improve overall survival in AEG patients compared to surgery alone, reducing death risk by 25% and 22%, respectively. Both treatment modalities show ...

BARCELONA – Adding preoperative chemoradiation to standard-of-care perioperative chemotherapy did not improve overall or progression-free survival in patients with resectable adenocarcinoma of the ...

CHICAGO -- A perioperative regimen of four cycles of chemotherapy before and after surgery extended overall survival (OS) compared with neoadjuvant chemoradiation in patients with locally-advanced, ...

A new UCLA investigator-initiated study sponsored by the UCLA Health Jonsson Comprehensive Cancer Center has found that ...

Ticiana Leal, MD, Winship Cancer Institutes, explains the importance of biomarker testing and multidisciplinary conversations while caring for patients with early-stage non–small cell lung cancer ...